| 伐尼瑞韦
|
|
IUPAC名
(1R,21S,24S)-21-tert-Butyl-N-((1R,2R)-1[(cyclopropylsulfonyl)amino]carbonyl2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
|
| 识别
|
| CAS号
|
923590-37-8
|
| PubChem
|
24765256
|
| ChemSpider
|
24651717
|
| SMILES
|
- CC(C)(C)[C@H]1NC(=O)OCC(C)(C)CCCCc2cccc3CN(Cc23)C(=O)O[C@H]4C[C@@H](N(C4)C1=O)C(=O)N[C@@]5(C[C@H]5C=C)C(=O)NS(=O)(=O)C6CC6
|
| EINECS
|
682-506-7
|
| ChEBI
|
136047
|
| DrugBank
|
DB11929
|
| KEGG
|
D09987
|
| 性质
|
| 化学式
|
C38H55N5O9S
|
| 摩尔质量
|
757.94 g·mol−1
|
| 外观
|
白色粉末
|
| 危险性
|
GHS危险性符号
|
| GHS提示词
|
警告
|
| H-术语
|
H373
|
| P-术语
|
P260, P314, P501
|
| 若非注明，所有数据均出自标准状态（25 ℃，100 kPa）下。
|
伐尼瑞韦（INN：Vaniprevir；开发代号：MK-7009）是一种大环丙型肝炎病毒（HCV）NS3/4A蛋白酶抑制剂，由默克公司开发，目前正在进行临床测试。[1]在日本，它于2014年被批准用于治疗丙型肝炎，商品名为Vanihep。[2][3]
参考资料[编辑]
- ^ McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J. Med. Chem. March 2010, 53 (6): 2443–63. PMID 20163176. doi:10.1021/jm9015526.
- ^ First recommendation for HCV drug vaniprevir, in Japan. datamonitorhealthcare.com. September 25, 2014.
- ^ New Drugs Approved (PDF). Pharmaceuticals and Medical Devices Agency.
